 5. Progressive disease according to PCWG2 criteria during prior therapy with standard dose of abiraterone acetate confirmed increase of PSA 25 over nadir or soft-tissue or bone progression. Patients that have stopped abiraterone acetate for reasons other than progression are not eligible. 